

Hepatitis C Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

<https://marketpublishers.com/r/H60F7A3CEFFBEN.html>

Date: June 2022

Pages: 340

Price: US\$ 2,500.00 (Single User License)

ID: H60F7A3CEFFBEN

Abstracts

Hepatitis C Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hepatitis C – Drugs In Development, 2022, provides an overview of the Hepatitis C (Infectious Disease) pipeline landscape.

Hepatitis C is a contagious viral infection affecting the liver. It may spread on contact with infected blood. It may be a mild condition or may extend over a longer span of time leading to various complications. The characteristic symptoms include abdominal pain, fatigue, fever, jaundice, loss of appetite, nausea and vomiting. The predisposing factors of hepatitis C include dialysis, organ transplant and blood transfusion. Offspring of an infected mother also has high chances of contracting the disease. Hepatitis C can be controlled with the help of medications or a transplant at an advanced stage.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hepatitis C – Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Hepatitis C (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press

releases.

The Hepatitis C (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Hepatitis C and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 3, 10, 8, 14, 30, 22 and 3 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 2, 13 and 17 molecules, respectively.

Hepatitis C (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Hepatitis C (Infectious Disease).

The pipeline guide reviews pipeline therapeutics for Hepatitis C (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Hepatitis C (Infectious Disease) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Hepatitis C (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Hepatitis C (Infectious Disease)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Hepatitis C (Infectious Disease).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Hepatitis C (Infectious Disease) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

- Introduction
- Global Markets Direct Report Coverage
- Hepatitis C – Overview
- Hepatitis C – Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Hepatitis C – Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Hepatitis C – Companies Involved in Therapeutics Development
- Hepatitis C – Drug Profiles
- Hepatitis C – Dormant Projects
- Hepatitis C – Discontinued Products
- Hepatitis C – Product Development Milestones
- Featured News & Press Releases
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Hepatitis C, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Number of Products under Development by Universities/Institutes, 2022 (Contd..1)
Products under Development by Companies, 2022
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Hepatitis C – Pipeline by AB Pharma Ltd, 2022
Hepatitis C – Pipeline by AbbVie Inc, 2022
Hepatitis C – Pipeline by Acceleromics SL, 2022
Hepatitis C – Pipeline by Apexian Pharmaceuticals Inc, 2022
Hepatitis C – Pipeline by Ascletis Pharma Inc, 2022
Hepatitis C – Pipeline by Atea Pharmaceuticals Inc, 2022
Hepatitis C – Pipeline by Auro Vaccines LLC, 2022
Hepatitis C – Pipeline by Beta Pharma Inc, 2022
Hepatitis C – Pipeline by Biotron Ltd, 2022
Hepatitis C – Pipeline by Bolder Biotechnology Inc, 2022
Hepatitis C – Pipeline by Bugworks Research India Pvt Ltd, 2022
Hepatitis C – Pipeline by Chia Tai Tianqing Pharmaceutical Group Co Ltd, 2022
Hepatitis C – Pipeline by Cocrystal Pharma Inc, 2022
Hepatitis C – Pipeline by ConserV Bioscience Ltd, 2022
Hepatitis C – Pipeline by DEKK-TEC Inc, 2022
Hepatitis C – Pipeline by Dongguan HEC TaiGen Biopharmaceuticals Co Ltd, 2022
Hepatitis C – Pipeline by Eagle Pharmaceuticals Inc, 2022
Hepatitis C – Pipeline by Ena Therapeutics Pty Ltd, 2022
Hepatitis C – Pipeline by Ennaid Therapeutics LLC, 2022
Hepatitis C – Pipeline by Escient Pharmaceuticals Inc, 2022
Hepatitis C – Pipeline by F. Hoffmann-La Roche Ltd, 2022
Hepatitis C – Pipeline by FortuneRock (China) Ltd, 2022
Hepatitis C – Pipeline by Galactica Biotech Ltd, 2022
Hepatitis C – Pipeline by GeneCure Biotechnologies LLC, 2022
Hepatitis C – Pipeline by GeneOne Life Science Inc, 2022

Hepatitis C – Pipeline by Genoscience Pharma, 2022
Hepatitis C – Pipeline by Gilead Sciences Inc, 2022
Hepatitis C – Pipeline by GSK plc, 2022
Hepatitis C – Pipeline by HEC Pharma Co Ltd, 2022
Hepatitis C – Pipeline by Hepion Pharmaceuticals Inc, 2022
Hepatitis C – Pipeline by ImmunoBiology Ltd, 2022
Hepatitis C – Pipeline by Inovio Pharmaceuticals Inc, 2022
Hepatitis C – Pipeline by Integrated BioTherapeutics Inc, 2022
Hepatitis C – Pipeline by iQur Ltd, 2022
Hepatitis C – Pipeline by J2H Biotech, 2022
Hepatitis C – Pipeline by Maxwell Biosciences Inc, 2022
Hepatitis C – Pipeline by Medivir AB, 2022
Hepatitis C – Pipeline by Merck & Co Inc, 2022
Hepatitis C – Pipeline by MetalloPharm LLC, 2022
Hepatitis C – Pipeline by Microbio Co Ltd, 2022
Hepatitis C – Pipeline by Nanjing Sanhome Pharmaceutical Co Ltd, 2022
Hepatitis C – Pipeline by Novalex Therapeutics Inc, 2022
Hepatitis C – Pipeline by Ono Pharmaceutical Co Ltd, 2022
Hepatitis C – Pipeline by Palisades Therapeutics, 2022
Hepatitis C – Pipeline by PharmaEssentia Corp, 2022
Hepatitis C – Pipeline by Presidio Pharmaceuticals Inc, 2022
Hepatitis C – Pipeline by Regulus Therapeutics Inc, 2022
Hepatitis C – Pipeline by Resilience Biotechnologies Inc, 2022
Hepatitis C – Pipeline by Riboscience LLC, 2022
Hepatitis C – Pipeline by Rodos BioTarget GmbH, 2022
Hepatitis C – Pipeline by Savoy Pharmaceuticals Inc, 2022
Hepatitis C – Pipeline by Shanghai Newsummit Biopharma Co Ltd, 2022
Hepatitis C – Pipeline by Shanghai Tangrun Pharmaceuticals Co Ltd, 2022
Hepatitis C – Pipeline by Shionogi & Co Ltd, 2022
Hepatitis C – Pipeline by Sino Biopharmaceutical Ltd, 2022
Hepatitis C – Pipeline by Statera Biopharma Inc, 2022
Hepatitis C – Pipeline by Sudershan Biotech Ltd, 2022
Hepatitis C – Pipeline by TaiGen Biotechnology Co Ltd, 2022
Hepatitis C – Pipeline by Tetranov International Inc, 2022
Hepatitis C – Pipeline by Toray Industries Inc, 2022
Hepatitis C – Pipeline by UBI Pharma Inc, 2022
Hepatitis C – Pipeline by Uvax Bio LLC, 2022
Hepatitis C – Pipeline by Vanworld Pharmaceutical (Rugao) Company Ltd, 2022
Hepatitis C – Pipeline by Vertex Pharmaceuticals Inc, 2022

Hepatitis C – Pipeline by Virocovax, 2022
Hepatitis C – Pipeline by Zylacta Corp, 2022
Hepatitis C – Dormant Projects, 2022
Hepatitis C – Discontinued Products, 2022

List Of Figures

LIST OF FIGURES

Number of Products under Development for Hepatitis C, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022

I would like to order

Product name: Hepatitis C Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/H60F7A3CEFFBEN.html>

Price: US\$ 2,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/H60F7A3CEFFBEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

